The first line treatment for uncomplicated falciparum malaria is artemisinin-based com-23 bination therapy (ACT), which consists of an artemisinin derivative co-administered with 24 a longer acting partner drug. However, the spread of Plasmodium falciparum resistant 25 to both artemisinin and its partner drugs poses a major global threat to malaria control 26 activities. Novel strategies are needed to retard and reverse the spread of these resistant 27 parasites. One such strategy is triple artemisinin-based combination therapy (TACT). 28 We developed a mechanistic within-host mathematical model to investigate the e cacy of 29 a TACT (dihydroartemisinin-piperaquine-mefloquine -DHA-PQ-MQ), for use in South- 30 East Asia, where DHA and PQ resistance are now increasingly prevalent. Comprehensive 31 model simulations were used to explore the degree to which the underlying resistance in-32 fluences the parasitological outcomes. The e↵ect of MQ dosing on the e cacy of TACT 33 was quantified at varying degrees of DHA and PQ resistance. To incorporate interactions 34 between drugs, a novel model is presented for the combined e↵ect of DHA-PQ-MQ, which 35 illustrates how the interactions can influence treatment e cacy. When combined with a 36 standard regimen of DHA and PQ, the administration of three 8.3 mg/kg doses of MQ 37 was su cient to achieve parasitological e cacy greater than that currently recommended 38 by WHO guidelines.
The e↵ect of the interaction parameter, ↵, on the e cacy was further assessed by restricting the resistance level to that corresponding to Chi Kraeng (EC 50,P 2 (69, 78]) 149 and estimating the probability of cure for di↵erent values of ↵; DHA resistance is also 150 assumed. The results demonstrated a significant di↵erence between the probabilities of 151 cure at di↵erent values of ↵; Fig. 4b . For example, when ↵ < 1 (synergism), one dose 152 of MQ was enough to provide 90% e cacy. In contrast, when ↵ > 1 (antagonism) the 153 probability of cure fell well below 90%. Similarly, the probability of cure declined with 154 increasing ↵ (i.e. antagonism intensification) for MQ administration on days 2 and 3 155 and on days 1, 2 and 3. Of note, the three 8.3 mg/kg doses of MQ achieved greater 156 than 90% e cacy at all values of ↵, even at levels indicative of very strong antagonism.
Discussion e cacy in several locations (9, 10, 11) . The addition of MQ to DHA-PQ has potential across a wide range of di↵erent scenarios reflecting varying parasite resistance to the di↵erent drug components. The results showed similar trends for di↵erent resistance 194 manifestations, confirming the robustness of the proposed dosing regimen of DHA- MQ. 196 We have proposed a novel empirical model to accommodate the e↵ect of the combined 197 drugs, assuming that PQ and MQ (both quinoline compounds) have similar modes of 198 action, which di↵ers from that of DHA (an endoperoxide compound). The killing e↵ects 199 of PQ-MQ and DHA were therefore assumed to be independent. This justified using a 200 combination of Bliss independence and Loewe additivity to define the combined e↵ect of 201 the whole compound (see Eqn. (1)).
202
To facilitate the dissemination of our model and assist clinical researchers to investi-203 gate how di↵erent PK and PD parameters and dosing schemes influence parasitological 204 outcomes, we have produced an online application that allows varying the values of pa- 
where g(a) accounts for the reduction in the number of circulating parasites in the blood 237 due to sequestration, estimated to be
where we assumed sequestration begins at age 11 and intensifies with age (16, 26). In the 239 ensuing section, we explain the details of modelling the combined e↵ect of the drugs, E.
240
The PK models for the three drugs considered, DHA, PQ and MQ, are well charac-241 terized; one-compartment models were used for DHA and MQ and a two-compartment 242 model for PQ (27, 28, 29 interaction when non-interacting drugs have similar modes of action, however, when the 258 drugs are believed to act independently, Bliss independence is more appropriate (31, 32).
259
It has been suggested that MQ and PQ kill parasites through a similar mechanism, 260 involving the disruption of haem detoxification in the parasite vacuole (33, 36, 37) . DHA 261 has a di↵erent mode of action, which involves the generation of free radicals and reactive 262 intermediates that target various proteins of parasites (36, 38, 39) . The PK and PD 263 interactions of DHA with PQ and MQ appear to be negligible (13).
264
The independent mechanisms of action of DHA and PQ-MQ justifies using the Bliss 265 independence concept for modelling the combined killing e↵ect, E, given by
where E D is the killing e↵ect of DHA and E P M is the combined e↵ect of PQ and MQ.
267
We assume Michaelis-Menten kinetics for E D :
is the concentration at which 50% of the maximum killing e↵ect is obtained; D is the 270 sigmoidicity (also known as slope) of the concentration-e↵ect curve; 1 W (a) is an indicator 271 function, used to implement the age-specific killing of drugs, defined by
where W is the age window (interval) where the antimalarial drugs are able to kill the 273 parasites; W D is the killing window of DHA.
274
To define E P M , models incorporating the Loewe additivity concept (as PQ and MQ 275 have similar modes of action) were used, which include only one parameter for the e↵ect 276 of the interaction between PQ and MQ (31, 32, 40) . These models are more specified 277 to the framework of drug interaction, in contrast to the statistical models that usually (40):
and
where E M is the killing e↵ect of MQ and E 1 P is the inverse of the killing e↵ect of PQ, 284 given by
where E max,P and EC 50,P are the maximum killing e↵ect of PQ and the concentration at 286 which half of the maximum killing e↵ect is produced, respectively; W P and W M are the 287 killing windows of PQ and MQ, respectively. Zero-interaction is produced by Eqn. (2) 288 when ↵ = 1; the values of 1 < ↵ < 1 and 0 < ↵ < 1 produce antagonism and synergism, 289 respectively. Note that PQ is considered to be more potent than MQ; see Supplementary
290
Material 2 for further information. can be inferred, respectively.
298
Using this approach, Davis et al. 2006 (13) showed that the paired PQ and MQ data were significantly above the zero-interaction isobole (dashed line), indicating a strong parasitaemia exceeded the microscopic limit of detection (50 parasite per µL or a total parasite biomass of 2.5 ⇥ 10 8 ). The mean values are shown along with the between-patient variabilities (presented as % 525 coe cient of variation) in brackets.
526 Table 2 Drug PK parameter DHA (28) MQ (27) Fig. S1 shows the results when E max,P varies across the deciles of its sampling interval; samples are taken from uniform distributions over each decile. Similar to the results of Section "Resistance to DHA", adding one dose of MQ to the ACT (blue curve) can increase the probability of cure, but is not su cient. In order to reach the probability of cure of above 90% for all of the deciles, we need three doses of MQ. Of interest, the magnitude of the e↵ect of resistance on probability of cure in this case is close to that of EC 50 ; resistance to DHA is also considered, i.e. EC 50,D 2 (50, 100].
Figure legends

Killing window, W
We now shorten the size of killing window, W , of PQ for the intra-erythrocytic parasite life cycle, by increasing the lower limit of the W and fixing the higher limit. The results for the ACT show that shortening the killing window can significantly reduce the probability of cure, but again, adding MQ to the compound can pull up the probabilities of cure. To achieve a probability of cure of at least 90%, three 8.3 mg/kg doses of MQ are required. Figure S2 : The probability of cure at day 42 of follow-up when the size of the parasite killing window (W ) for PQ is reduced by increasing the lower limit, W l , from 12 to 30. 
where C P and C M are the concentrations of PQ and MQ, respectively, and 0 , . . . , 3 are the coe cients of the model. Similar statistical models can be found in (42, 43) .
Another set of models include only one parameter to incorporate the e↵ect of interaction (31, 40, 32) . These models are more specified to the framework of drug interaction, in contrast to the statistical models. Here, we focus on the models with one parameter of interaction -noting that statistical models are shown to be readily transformable to these models, e.g. see (41).
One of the most frequently used models to describe the combined e↵ect is Greco's model (31), defined by 1 = C P Then, the zero-interaction model is obtained via
(2.4) Subsequently, Eqn. (2.4) can be modified to accommodate an interaction between drugs. For example, Tallarida (2000) suggests changing this equation to C P M /↵, where ↵ is the interaction parameter. However, we dismiss this method as it does not produce the observed antagonistic isoboles (see Fig. 5 ), hence, it will not provide a good fit to data. In order to obtain a form of E P M similar to Greco's model, Eqn. (2.3), we then modified Eqn. (2.4) to incorporate the e↵ect of an interaction between drugs. Adding ↵C P C eq,M as an extra term to this equation provides a good fit to the data for ↵ = 0.132, but, the resultant E P M is non-monotonic, which is biologically infeasible. We also tried other terms such as ↵ p C P C eq,M , but they similarly failed to give either a good fit or a monotonic e↵ect. Hence, the models of form Eqn. (2.3) did not produce an appropriate E P M , as also outlined by White et al. (2003) and Machado, Robinson (1994) .
We then turned to using the model introduced by Machado, Robinson (1994):
where zero-interaction is produced when ↵ = 1. The values of 1 < ↵ < 1 and 0 < ↵ < 1 produce antagonism and synergism, respectively. The model provides a good fit to the data (see Fig. 5a ), and importantly, a biologically feasible killing e↵ect, E P M (see Fig.   5b ). Therefore, we selected this model for E P M , and used it in the combined e↵ect, Eqn.
(1), of the TACT.
To conform with the data provided by Davis et al. (2006) (13), the maximum killing e↵ects and sigmoidicity of PQ and MQ are considered equal (i.e. E max,P = E max,M = 0.3 and P = M = 3) throughout the model fitting. However, the considered range of variation for ↵ in the simulations is significantly larger than the potential variations due to E max,P 6 = E max,M and/or P 6 = M , hence, these assumptions do not invalidate the results (see Table 3 ).
3 Calculating E max using the parasite reduction ratio (PRR)
We are interested in finding how E max is related to the parasite reduction ratio (PRR).
We can estimate PRR by
where T is the time when we count the number of parasites (e.g. T = 48 hrs) to calculate PRR, and N 0 is the initial number of parasites at time t 0 . Then, we have
(1 E(a ⌧ , t 0 + ⌧ )) = N 0 PMF ⇥ PRR ,
8
where a ⌧ = [(a + ⌧ ) mod 48]. Thus, we use numerical methods to solve the above equation for E max . The estimated E max values are listed in Table 3 . Note that it is extremely important to take account of the details of the clinical e cacy studies, by which the PRRs of the drugs are obtained. We used the following PRRs and the dosing regimens to estimate E max for each drug:
• PRR DHA = 10 4 : seven 2 mg/kg doses of DHA are administered (51).
• PRR P Q = 2951: one 14.1 mg/kg dose of PQ is administered (52).
• PRR MQ = 100: one 25 mg/kg dose of MQ is administered (51).
The obtained E max is then used as the median of the triangular distribution (see Table   3 ), and the lower and higher limits of the distribution are found by E max,l = E max log(50) ||W || ,
where ||W || is the size of killing window of the drug (17).
